Long-term follow-up of over 1000 patients with salivary gland tumours treated in a single centre.
Between 1947 and 1992, 1403 patients with 1432 salivary gland tumours were treated at the Christie Hospital, Manchester. There were 1194 epithelial neoplasms: parotid, 1082 (91 per cent); submandibular, 47 (4 per cent); minor glands, 65 (5 per cent). The commonest histological diagnoses were pleomorphic adenoma (n = 776) and adenolymphoma (n = 159). A total of 244 carcinomas were seen (adenoid cystic carcinoma, n = 75). Treatment was primarily surgical, conservative where possible, and determined by tumour extent and not histology. Adjuvant radiation therapy was used in over half the definitively treated malignancies. The recurrence rate following the treatment of 551 new parotid pleomorphic adenomas was 1.6 per cent at median follow-up 12.5 (range 1-34) years, increasing to 15 per cent in the secondarily referred group (n = 170). For patients with definitively treated primary salivary carcinomas (n = 148), the disease-free survival rate at 5, 10 and 15 years was 58, 47 and 45 per cent respectively. Using multivariate analysis, clinical stage was the most important predictor of survival; the 10-year survival rate for stages I-IV was 96, 70, 47 and 19 per cent respectively.
Renehan
A
A
University Department of Surgery, University Hospital of South Manchester, UK.
Gleave
E N
EN
Hancock
B D
BD
Smith
P
P
McGurk
M
M
D000235:Adenolymphoma / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D008949:Adenoma, Pleomorphic / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D003528:Carcinoma, Adenoid Cystic / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012017:Referral and Consultation; D012307:Risk Factors; D012468:Salivary Gland Neoplasms / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D013365:Submandibular Gland Neoplasms / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy; D015996:Survival Rate; D017211:Treatment Failure